Related Experiment Video
Updated: May 30, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Insulin initiation and intensification: insights from new studies
1Diabetes Care and Research Centre, G.C.I.B, Kankerbagh, Patna, 800 020, India.
Achieving target blood glucose levels in type 2 diabetes is crucial for preventing complications. Insulin intensification strategies, particularly using BIAsp 30, are key when initial therapies fail to meet glycemic goals.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Tight glycemic control is essential for mitigating macrovascular and microvascular complications in type 2 diabetes.
- Many patients with type 2 diabetes fail to achieve target HbA1c levels (< 7%) despite treatment.
- Postprandial glucose excursions significantly contribute to hyperglycemia, necessitating intensified insulin regimens.
Purpose of the Study:
- To review the role of insulin intensification in type 2 diabetes management.
- To highlight BIAsp 30 as a frequently prescribed analog premix for optimizing glycemic control.
- To discuss the evidence supporting BIAsp 30 for regimen intensification from once-daily (OD) to twice-daily (BID) and from BID to thrice-daily (TID).
Main Methods:
- Review of randomized controlled trials (RCTs) and observational data on insulin therapy in type 2 diabetes.
- Analysis of insulin intensification strategies, focusing on premixed insulin analogs.
- Examination of BIAsp 30 usage patterns and evidence base.
Main Results:
- BIAsp 30 possesses the largest evidence base among analog premixes due to extensive RCTs and observational data.
- BIAsp 30 is frequently utilized for insulin intensification, transitioning from basal insulin or from OD to BID and BID to TID regimens.
- Effective intensification is crucial for patients not meeting glycemic targets.
Conclusions:
- Insulin therapy requires optimization and intensification to achieve glycemic targets in type 2 diabetes.
- BIAsp 30 is a well-supported analog premix for intensifying insulin regimens.
- Strategic intensification using BIAsp 30 can improve glycemic control and potentially reduce long-term complications.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin: The Receptor and Signaling Pathways
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...

